

GM Policy:	<u>Hair Replacement Technologies Policy</u>		
GM Ref:	GM069	Current version:	2.1 (21 Mar 2018)
Policy exclusions (Alternative commissioning arrangements apply)			
<p>Hair loss (other than male pattern baldness which is considered to be a normal variant) should be investigated and any underlying cause treated as clinically appropriate.</p> <p>NHS wigs supplied as part of an agreed clinical pathway (for example, cancer is excluded from this policy).</p> <p>Treatment/procedures undertaken as part of an externally funded trial or as a part of locally agreed contracts / or pathways of care are excluded from this policy, i.e. locally agreed pathways take precedent over this policy (the EUR Team should be informed of any local pathway for this exclusion to take effect).</p>			
Policy inclusion criteria			
<p>There are no mandatory criteria as hair replacement systems are considered to be aesthetic treatments and are <u>not</u> routinely commissioned.</p> <p>These technologies are <u>not</u> commissioned for failure of hair to re-grow following the end of a course of treatment that caused the initial loss.</p>			
<p>Funding Mechanism: Individual funding request (exceptional case) approval: Requests <u>must</u> be submitted with all relevant supporting evidence.</p>			
Clinical Exceptionality:	Clinicians can submit an Individual Funding Request (IFR) outside of this guidance if they feel there is a good case for exceptionality.		
GM Shared Services EUR Team:	Email: gmifr.gmcsu@nhs.net / Tel: 0161 212 6250		